Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors

Key clinical point: Routine pneumocystis jiroveci pneumonia prophylaxis may be unwarranted in chronic lymphocytic leukemia patients initiating Bruton tyrosine kinase inhibitor therapy.

Major finding: Pneumocystis jiroveci pneumonia incidence in patients on prophylaxis was 0% versus 3.4% for patients not receiving prophylaxis. The number needed to treat to prevent 1 case was 42 patients.

Study details: A retrospective chart review involving 212 patients.

Disclosures: Dr. Ryan reported having no financial disclosures.


Ryan C et al. iwCLL 2019, Abstract 1941.